On September 13, PTC Therapeutics’ stock price closed at $47.33, which is ~0.66% growth from the close of $47.02 the previous day.
On September 13, PTC Therapeutics’ stock price closed at $47.33, which represents ~264% growth from its 52-week low of $14.56 on September 26, 2017.
Notably, PTC Therapeutics’ stock price hit its 52-week high of $52.95 on June 18. PTC Therapeutics’ stock price grew from $17.46 on January 2 to 47.33 on September 13, which represents ~203% year-to-date growth.
In August, PTC Therapeutics completed the acquisition of Agilis Biotherapeutics. The acquisition addeds Agilis Biotherapeutics’ important portfolio GT-AADC, an adeno-associated virus gene therapy that has the potential to treat Aromatic L-Amino Acid Decarboxylase deficiency, into PTC Therapeutics’ portfolio. PTC Therapeutics also added other gene therapy programs to its portfolio like GT-FA, GT-AS, and GT-RLN.
The GT-FA gene therapy program is associated with Friedreich Ataxia, while the GT-AS gene therapy program is associated with cognitive disorders related to Angelman syndrome. The GT-RLN gene therapy program is associated with various neurodegenerative disorders.
In the second quarter, Translarna witnessed 4% growth year-over-year to $47.8 million from 45.8 million in the second quarter of 2017.
In the second quarter, Emflaza generated net revenues of $20.3 million—compared to $2.1 million in the second quarter of 2017.
Of the eight analysts tracking PTC Therapeutics in September, two recommended a “strong buy,” while two recommended a “buy.” Three analysts recommended a “hold” and one recommended “sell” rating for PTC Therapeutics in September.
On September 13, PTC Therapeutics had a consensus 12-month target price of $42.17, which is an ~10.90% decline over the next 12 months.
On September 13, Sarepta Therapeutics and Amicus Therapeutics had consensus 12-month target prices of $188.58 and $20.0, respectively, which is an ~25.54% and ~72.41% return on investment over the next 12 months.